Pilot Study of Lucentis Combined With Proton Beam Irradiation in Treating Wet Age-related Macular Degeneration
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
Because a possible synergism of radiation and inhibitors of vascular endothelial growth
factor has been shown in cancer patients and patients with wet macular degeneration, this
pilot study is being conducted to determine whether treating wet macular degeneration with a
combination of Lucentis and proton beam irradiation is safe. Lucentis is an inhibitor of
vascular endothelial growth factor which was recently FDA approved for treatment of wet
macular degeneration. It appears to be the most effective therapy thus far for wet macular
degeneration among all drugs FDA approved for this condition. If no major safety issues are
associated with this combination therapy, a larger study will be conducted to determine
whether this combination therapy is more effective than Lucentis monotherapy.
Phase:
Early Phase 1
Details
Lead Sponsor:
University of California, Davis
Collaborators:
Genentech, Inc. University of California, San Francisco